# Thermo Fisher Scientific (TMO) — InvestMoat Analysis

_Last analyzed: May 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/tmo_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 80 |
| Growth trajectory | 61 |
| Valuation | 78 |
| **Composite** | **73** |
| **Recommendation** | **Hold** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** TMO
- **Market Cap:** ~$181B

## Moat

Lab-tools and bioprocessing razor-blade with FDA-validated workflows that make switching prohibitively expensive in regulated pharma manufacturing.

### The FDA-Validated Workflow Moat

Thermo Fisher's moat is the **regulatory cost of switching** — once a TMO instrument is validated for cGMP production, swapping it requires re-running the full regulatory submission:

- **FDA-Validated Switching Cost:** When a pharma customer validates a TMO instrument or reagent for cGMP production, replacing it requires full process revalidation — months of work, $millions in cost, and tapeout-equivalent regulatory risk. This is the dominant moat for the bioproduction segment.
- **Razor-Blade Economics:** TMO sells the instrument once, then captures recurring consumables, reagents, and service revenue at high margins for the instrument's 8-15 year life. Roughly 80% of revenue is recurring consumables/service — the installed base compounds even when capex slows.
- **M&A Compounding Engine:** TMO has a 30-year track record of acquiring scientific tooling companies (Life Tech, Patheon, PPD, Thermo Electron, Olink, Clario) and bolting them onto the global commercial channel. The bolt-on model adds 2-3pp of growth above organic in most years.

**Moat verdict:** Thermo Fisher is a moderate AI beneficiary. The strongest moats — regulatory lock-in, transaction embedding, and the bundling razor-blade — are AI-neutral or AI-strengthened (AI assists method development without disrupting the regulatory cost-of-switching). The AI-vulnerable categories (learnedInterfaces, businessLogic, talentScarcity) are merely intact rather than destroyed because regulated workflows protect them. Sits in the healthcare peer range (80-90) alongside ISRG/LLY, just below the financial-data oligopoly tier.

## Growth

Q1 2026 revenue +6% YoY ($11.01B) with only +1% organic — pharma/biotech bioprocessing recovery is partial. FY26 guide raised to $47.3-48.1B (6-8% reported, 3-4% organic) and adj EPS $24.64-25.12 (+8-10%). Pharma & biotech leading; tariff drag (80bps) compressing op margin near term.

- **Revenue CAGR estimate:** 6-9%
- **Primary type:** both
- **Margin trend:** compressing
- **Key risk (moderate):** If pharma/biotech bioproduction capex stays soft through 2H 2026 with organic growth stuck below 3%, EPS guidance is at risk and the multi-year compounder narrative requires the next bolt-on to re-anchor — testing the 8-10% EPS-growth thesis.
- **Drivers:**
  - Life Sciences Solutions — +13% reported, +1% organic in Q1 2026 (bioproduction recovering) (stable)
  - Lab Products & Biopharma Services — +7% reported, +4% organic (clinical research strong) (accelerating)
  - M&A Bolt-Ons (Clario) — $0.01 EPS contribution Q1; full-year accretion to ramp (stable)
- **Score derivation:** Base 60 (4-8% blended organic + bolt-on M&A puts top of range near 8% boundary) + 5 recurring (~80% consumables/service) + 2 TAM expansion (Clario clinical trial services) - 5 cyclical pharma/biotech end-market = 62

## Valuation

At ~$487 the stock has recovered off its lows but still sits ~24% below the 52-week high of $643.99 and ~22% above the bear case. Forward P/E of ~19× remains well below the healthcare-tools sector median (~24-28×) and TMO's own 5-year average. RBC Capital restarted coverage in late May 2026 (Sector Perform, $490 PT), and management used the May Investor Day to reaffirm the long-term compounder framework and the $0.47 quarterly dividend. The market is still pricing in bioprocessing softness; the consensus analyst target of ~$580-620 implies meaningful re-rating if organic growth re-accelerates.

| Multiple | Value | Note |
| --- | --- | --- |
| Trailing P/E (GAAP) | ~25× | TTM GAAP EPS depressed by acquisition charges |
| Forward P/E (NTM) | ~19× | $24.88 mid 2026 EPS guide |
| PEG Ratio | ~2.1× | fwd P/E ÷ ~9% EPS CAGR |
| Price / Sales (NTM) | ~3.7× | $47.7B mid 2026 revenue |
| Price / FCF | ~24× | FCF conversion ~80% of net income |

Forward P/E of ~19× is a meaningful discount to the healthcare-tools sector median (~24-28×), reflecting the bioprocessing softness already in the price. PEG ~2.1 sits in the 'premium-but-defensible' band given the recurring revenue base. The trailing-vs-forward gap signals the EPS ramp from Clario integration and bioproduction recovery rolling through 2026 numbers. A pending microbiology-business divestiture would modestly sharpen portfolio focus. _(as of May 2026)_

## Price scenarios

### Bear — $400

Bioprocessing recovery stalls into 2027, organic growth stays at 1-2%, tariff drag persists, and the multiple compresses toward 16× forward earnings.

- Pharma/biotech capex remains soft, organic growth stuck at 1-2% through 2026 and 2027
- Tariff and FX drag persist, compressing adjusted op margin below 21.5%
- Forward P/E re-rates to ~16× as the slow-organic narrative becomes structural

### Base — $560

FY26 guide hits midpoint ($47.7B / $24.88 EPS), organic growth re-accelerates to 4-5% in 2H, multiple holds at ~22× forward.

- Organic growth re-accelerates to 4-5% in 2H 2026 as bioproduction inventory destocking ends
- Clario integration contributes >$0.30 to 2027 EPS, M&A bolt-on cadence resumes
- Adj op margin recovers to 22.5%+ as tariff impact annualises and productivity programs offset

### Bull — $700

Bioprocessing fully recovers to mid-single-digit organic growth, M&A pipeline delivers a transformational deal, and multiple expands toward TMO's 5-year average ~26× forward.

- GLP-1 manufacturing capacity buildouts and biologics pipeline drive bioproduction back to 8%+ organic
- Transformational M&A deal (>$10B) in clinical trials, diagnostics, or specialty consumables
- Forward P/E re-rates to 24-26× as compounder narrative reasserts; EPS power approaches $28 by 2027

---

InvestMoat is an open-source research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.